|
Faron Pharmaceuticals Ltd on Monday said further data from its Phase I/II MATINS study of bexmarilimab has indicated the efficacy and safety of the immunotherapy in solid tumours. The Turku, Finland-based biopharmaceutical drug discovery and development company said bexmarilimab monotherapy leads to disease control and prolonged survival in late-stage cancer. Bexmarilimad is a humanised, anti-CLEVER-1 antibody that helps the immune system to attack tumours. The firm added that when the CLEVER-1 immunosuppressive receptor, which leads to tumour growth and metastases, is targeted, the therapy is well tolerated by patients. Chief Scientific Officer Maija Hollmen said: ‘We are very pleased to see that bexmarilimab is well-tolerated and has promising antitumour activity as a single agent in late-stage solid tumour. ‘This manuscript brings together clinical safety and efficacy data with in-depth analyses of tumour biopsies and systemic inflammatory responses. Excitingly, it reinforces the evidence that macrophage conversion in the tumour takes place after bexmarilimab administration and coincides with treatment benefit.’ Faron shares rose 1.3% to 323.20 pence each in London on Monday afternoon. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
